Olutasidenib is a small-molecule inhibitor of mutated IDH1. The Food and Drug Administration (FDA) has approved Rezlidhia™ (olutasidenib) for the treatment of adult patients with relapsed or ...

On the heels of a $278 million IPO, Forma Therapeutics is inching toward its first FDA filing. Its lead asset, an IDH1 inhibitor, cleared cancer in one-third of patients with acute myeloid leukemia ...

The findings suggest that sequential mutant IDH inhibitor therapy might be one way to fight resistance in metastatic intrahepatic cholangiocarcinoma (IHCC). A new report is shedding light on how some ...

The approval was based on data from the double-blind, placebo-controlled ClarIDHy study. The Food and Drug Administration (FDA) has approved Tibsovo ® (ivosidenib) for the treatment of adult patients ...

Ivosidenib monotherapy is now approved by the FDA for patients with relapsed/refractory myelodysplastic syndrome with an IDH1 mutation. In conjunction with ivosidenib’s approval, the FDA also approved ...

Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study Twenty-one patients (escalation, n = 12; ...

A new article published in the journal Nature is reporting promising results from a landmark Phase 1 human trial testing a novel vaccine designed to help a patient's immune system better target brain ...

A British man who rejected the standard of care to treat his brain cancer has lived with the typically fatal glioblastoma tumor growing very slowly after adopting a ketogenic diet, providing a case ...

A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a ...

Voranigo and Temodar combination showed no serious side effects or dose-limiting toxicities in IDH1/2-mutant glioma patients. Treatment-emergent side effects led to dose reductions in 42.9% of ...